Functional validation of projection topography in the nigrostriatal dopamine system.
Anatomical investigations have revealed that the nigrostriatal pathway is topographically organised. In two experiments, nigrostriatal topography was investigated with catecholamine specific procedures, using paradigms which reflect the functional activity of dopaminergic neurones. Data were analysed with the intention of discovering possible relationships between the mesencephalic location of stimulating electrodes or injection cannulae, the extent and location of dopamine histofluorescence depletion within the striatum, and the effects of amphetamine and apomorphine on rotational behaviour. In animals pretreated with 250 mg/kg alpha-methyl-p-tyrosine it was found that unilateral stimulation with medially-placed nigral electrodes produced maximal depletion of dopamine histofluorescence in anterior dorso-medial regions of the striatum, while laterally-located electrodes principally depleted posterior, ventro-lateral areas. In the second experiment, 2 micrograms of 6-hydroxydopamine in a volume of 0.5 microliter was injected unilaterally at varying loci within the ventral midbrain of animals pre-treated with desmethylimipramine (25 mg/kg). It was discovered that the lateral injection coordinate was significantly associated with both the extent and location of the depletion of dopamine-related fluorescence from the ipsilateral striatum. Rotational behaviour, induced by dopamine-agonists was related firstly, to the overall extent of dopamine depletion from the striatum, and secondly, the contraversive turning induced by apomorphine in particular was related to the dorsoventral coordinate of the mesencephalic 6-hydroxydopamine injection. The results provide functional validation for the pattern of topographical projection within the nigrostriatal dopaminergic system proposed on the basis of intracellular tracing techniques.
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002421:Caudate Nucleus / Q000502:physiology; D003342:Corpus Striatum / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D008636:Mesencephalon / Q000502:physiology; D008781:Methyltyrosines / Q000494:pharmacology; D009043:Motor Activity / Q000502:physiology; D016627:Oxidopamine; D051381:Rats; D012399:Rotation; D013378:Substantia Nigra / Q000502:physiology*; D019805:alpha-Methyltyrosine
D006892:Hydroxydopamines; D008781:Methyltyrosines; D019805:alpha-Methyltyrosine; D016627:Oxidopamine; D000661:Amphetamine; D001058:Apomorphine; D004298:Dopamine